Breast Cancer Canada announces $500K in new grant funding
December 01, 2022 13:58 ET | Breast Cancer Canada
SARNIA, Ontario, Dec. 01, 2022 (GLOBE NEWSWIRE) --  Breast Cancer Canada today announced a call for proposals for their 2023 Precision Oncology Research Grants which will award $500,000 in new...
22157.jpg
Immuno-oncology Global Market Report 2022: Approval of Novel Therapies Boosts Sector Growth
November 30, 2022 05:48 ET | Research and Markets
Dublin, Nov. 30, 2022 (GLOBE NEWSWIRE) -- The "Immuno-oncology Market Size, Share, Trends, Analysis and Forecast by Region, Segment, Type (Checkpoint Modulators, Cancer Vaccines) and End-User...
Sunshine Biopharma Logo
Sunshine Biopharma Enters Into a Collaboration Agreement with a Leading Lipid Nanoparticle Formulation Company for Its K1.1 Anticancer mRNA Project
November 16, 2022 08:00 ET | Sunshine Biopharma Inc.
MONTREAL, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas,...
FRED’S TEAM MAKES HISTORY BY RAISING $100 MILLION FOR CANCER RESEARCH
November 03, 2022 09:00 ET | Memorial Sloan Kettering Cancer Center
NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Fred’s Team, MSK’s running program, has made history by surpassing $100 million in total funds raised for cancer research. Since 1995, runners have joined...
Florida Cancer Specialists & Research Institute Leaders Serve on Faculty for Value-Based Cancer Care Summit
October 19, 2022 14:00 ET | Florida Cancer Specialists & Research Institute
Fort Myers, Fla., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Fort Myers, Fla., October 19, 2022 – Senior leaders of Florida Cancer Specialists & Research Institute (FCS) will serve on the faculty for...
ptx-logo .png
Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader
October 18, 2022 08:00 ET | Prelude Therapeutics, Inc.
WILMINGTON, Del., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that the U.S. Food and...
22157.jpg
Global Oncology Nutrition Market Report 2022: A $2.13 Billion Market in 2026 Featuring B. Braun Melsungen, Danone India, Abbott Laboratories, Nestle, Victus
October 06, 2022 06:13 ET | Research and Markets
Dublin, Oct. 06, 2022 (GLOBE NEWSWIRE) -- The "Oncology Nutrition Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.The global oncology nutrition market is...
Science Crossing Borders: Celebrating the Contributions of Immigrant Scientists
October 05, 2022 09:45 ET | The Vilcek Foundation
NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) -- They come from around the world—born in Taiwan, India, Lebanon, Israel, Romania, and Russia, among other places—but they all call the United States home....
logo 600X600.png
Global Cell Culture Market to Surpass US$ 33,452.8 Million by 2030, Says Coherent Market Insights (CMI)
September 29, 2022 09:15 ET | CMI
Seattle, Sept. 29, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global cell culture market is estimated to be valued at US$ 19,198.0 million in 2022 and is expected to exhibit...
Elevar Logo for Common Use.png
Elevar Therapeutics Announces Camrelizumab Plus Rivoceranib Significantly Prolonged Overall Survival and Progression-Free Survival Versus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma During Phase 3 Trial, a Joint Program With Hengrui Pharma
September 10, 2022 04:00 ET | Elevar Therapeutics
Top-line findings were presented today at the annual European Society for Medical Oncology (ESMO) Congress This is the first positive pivotal trial to show survival benefits with a PD-1 inhibitor...